Concentration of MitoQ in Human Skeletal Muscle

NCT ID: NCT04098510

Last Updated: 2019-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-08

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine mitoquinone mesylate concentration levels in skeletal muscle samples obtained after intake of an acute oral dose of MitoQ.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MitoQ

Subjects ingest 160 mg of MitoQ

Group Type EXPERIMENTAL

MitoQ

Intervention Type DIETARY_SUPPLEMENT

Subjects ingest 8x20 mg MitoQ capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MitoQ

Subjects ingest 8x20 mg MitoQ capsules

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy,
* Male
* 18-40 years of age

Exclusion Criteria

* Previous use of MitoQ or CoQ-10 within 30 days of screening appointment
* Ongoing use of MitoQ
* Smoking
* Ongoing treatment with medications
* Disease deemed by the MD to infer a risk to participate in the trial
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Morten Hostrup, PhD

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

August Krogh Building

Copenhagen, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Morten Hostrup, PhD

Role: primary

+4524474785

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MitoQ

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Resistance Exercise in Healthy Men
NCT01220037 COMPLETED NA
Proteome Remodelling
NCT04136457 COMPLETED NA
Creatine and Motor Skill Acquisition
NCT05201651 UNKNOWN EARLY_PHASE1
C-Protein in Fatigue and Aging
NCT05926219 RECRUITING NA